comparemela.com
  1. Home
  2. Live Updates
  3. Hansa Biopharma Ab - Breaking News

Latest Breaking News On - Hansa biopharma ab - Page 5 : comparemela.com

Hansa Biopharma Nomination Committee formed

/PRNewswire/ Hansa Biopharma today announced that the Nomination Committee has been formed in accordance with the principles adopted by the Annual General.

Hansa biopharmaArne myhrmanNatalie bernerKlaus sindahlPeter nicklinThomas olaussonJannis kitsakisNomination committeeRedmile groupPr nomination committeeAnnual general meetingAbuse regulationHansa biopharma ab

Hansa Biopharma and partner Sarepta Therapeutics plan to initiate a clinical study with imlifidase as a pre-treatment to Sarepta s SRP-9001 gene therapy in DMD in 2023

/PRNewswire/ Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced that.

Hansa biopharmaKlaus sindahlNational institutes of healthNasdaq stockholmSarepta therapeuticsBiologics license applicationGenetics homeHansa biopharma ab

Hansa Biopharma to host conference call to provide interim results for January-September 2022 and Business Update

/PRNewswire/ Hansa Biopharma AB (NASDAQ Stockholm: HNSA) will publish its interim report for January-September 2022 at 8:00 CET on October 20, 2022. All.

United statesUnited kingdomVastra gotalands lanSan franciscoHansa biopharmaPrnewswire hansa biopharmaKlaus sindahlDonato spotaBryan garnierHealth careInterim reportRedeye after workRedeye lunchUgebrev life science conferenceRedeye life science dayErik penser banks temadag

Hansa Biopharma achieves Great Place to Work® certification for the third consecutive year

/PRNewswire/ Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), the pioneer in enzyme technology for rare immunological conditions, today announced its.

Hansa biopharmaKlaus sindahlCompanies to workGreat placeNasdaq stockholmBest workplacesWork forHansa biopharma abHealth care amp hospitalsMedical pharmaceuticalsHuman resource amp workforce managementOlls and research

Hansa Biopharma: Increase of the number of shares and votes

/PRNewswire/ Hansa Biopharma AB "Hansa" or the "Company", (NASDAQ Stockholm: HNSA), the pioneer enzyme technology for rare immunological conditions, today.

Hansa biopharmaPrnewswire hansa biopharmaKlaus sindahlFinancial instruments tradingHansa biopharma abHealth care amp hospitalsMedical pharmaceuticalsAccounting news amp issues

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.